Efficacy and safety of GLP-1RAs, SGLT2is, and nsMRAs for cardiovascular and renal outcomes in T2DM with CKD: a systematic review and network meta-analysis.

Chen H, Wu X, Yuan M, Ren F, Liu T, Yang L, An X, Zhan Y

Open source

DOI
10.3389/fendo.2026.1937754
Published
2026
Container
Frontiers in endocrinology
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3389/fendo.2026.1937754,
  title = {Efficacy and safety of GLP-1RAs, SGLT2is, and nsMRAs for cardiovascular and renal outcomes in T2DM with CKD: a systematic review and network meta-analysis.},
  author = {Chen H and Wu X and Yuan M and Ren F and Liu T and Yang L and An X and Zhan Y},
  year = {2026},
  journal = {Frontiers in endocrinology},
  doi = {10.3389/fendo.2026.1937754},
  url = {https://doi.org/10.3389/fendo.2026.1937754}
}

RIS

TY  - JOUR
TI  - Efficacy and safety of GLP-1RAs, SGLT2is, and nsMRAs for cardiovascular and renal outcomes in T2DM with CKD: a systematic review and network meta-analysis.
AU  - Chen H
AU  - Wu X
AU  - Yuan M
AU  - Ren F
AU  - Liu T
AU  - Yang L
AU  - An X
AU  - Zhan Y
PY  - 2026
JO  - Frontiers in endocrinology
DO  - 10.3389/fendo.2026.1937754
UR  - https://doi.org/10.3389/fendo.2026.1937754
ER  - 

APA

H, C., X, W., M, Y., F, R., T, L., L, Y., X, A., & Y, Z. (2026). Efficacy and safety of GLP-1RAs, SGLT2is, and nsMRAs for cardiovascular and renal outcomes in T2DM with CKD: a systematic review and network meta-analysis.. Frontiers in endocrinology. https://doi.org/10.3389/fendo.2026.1937754

Source records